Aerie Pharma (AERI) Price Target Lowered to $27 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Micron to deliver 'another strong quarter', Goldman says
- Salesforce to acquire metering platform M3TER for consumption billing
Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results
April 23, 2015 4:01 PM EDTConference Call and Webcast Today, April 23 at 5:00 p.m. ET
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma... More
